http://www.pharmj.com/Editorial/20021026/news/otcaspirin.html
Home >
PJ (current issue) >
News / Daily News
| Search
| The Pharmaceutical Journal Vol 269 No 7221 p593 26 October 2002 |
| News summary |
OTC aspirin ban likely to be extended to all under 16s
|
Reye’s syndromeReye’s syndrome is a rare brain and liver disorder than can be fatal.
It is found almost exclusively in children and occurs mainly in those
under the age of five years. A small number of cases have |
The announcement follows earlier recommendations from the Committee on Safety of Medicines that aspirin should be avoided in children aged up to and including 15 years if they are feverish and that the ban in under-12-year-olds should remain (PJ, 27 April, p557). These restrictions were thought to be necessary because of the small risk of Reye’s syndrome among 12- to 15-year-olds who have a fever and who take aspirin (see Panel). However, the CSM reviewed its recommendations at its October meeting and decided that because aspirin products are on general sale the advice was too complicated.
Professor Alasdair Breckenridge, chairman of the CSM, said: “The risk of Reye’s syndrome in 12- to 15-year-olds is small but there have been concerns that earlier advice was too complex for products that are available on general sale — in the supermarket and corner shop — requiring a diagnosis of fever by a parent or minor.
“There are plenty of analgesic products containing paracetamol and ibuprofen for this age group not associated with Reye’s syndrome. There is simply no need to expose those under 16 to the risk, however small.” He added that parents and children should talk to a pharmacist if they have any questions.
The MCA has launched an eight-week public consultation on the proposed changes to warnings for aspirin products. The full consultation document is available on the MCA website (www.mca.gov.uk). Comments can be sent to Jeremy Mean, MCA, Market Towers, 1 Nine Elms Lane, London SW8 5NQ, by 31 December.
Subject to the outcome of this consultation, the MCA says that a statutory instrument will be laid before Parliament with the requirement for new warnings coming into force around March 2003.
Home | Journals | News | Notice-board | Search | Jobs Classifieds | Site
Map | Contact us
©The
Pharmaceutical Journal
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.